Transactions

  • Sale of
  • to
  • $189,000,000

  • Partnering of
  • 2 FDA Approved Assets with
  • $430,000,000

  • Partnering of
  • Phase 3 safinamide with
  • $200,000,000

  • Partnering of
  • DGAT-1 Inhibitors with
  • Not Disclosed

  • Partnering of ex-US rights
  • Phase 3 Desmoteplase with
  • €65,000,000

  • Sale of
  • to
  • Not Disclosed

  • Raised Series C
    Private Placement
  • €16,000,000

  • Partnering of
  • Phase 2 RP101 with
  • €13,000,000

  • Partnering of
  • Phase 3 Desmoteplase with
  • $69,500,000

  • Partnering of
  • Phase 2 P93/01 with
  • $35,000,000

  • Partnering of
  • Pre-Clinical CRB-15 with
  • $90,000,000

  • Advising Shareholders
  • In Sale to
  • $320,000,000

  • Raised Series F
    Preferred Stock
  • $30,000,000

  • Sale of
  • to
  • Not Disclosed

  • Raised first financing Series A, Series B & Common Stock
  • $3,000,000

GO BACK▲